Zimmer Biomet Holdings (ZBH) : The money flow is calculated as the dollar value of composite uptick trades minus the dollar value of downtick trades, which was negative (8.09 million) in Zimmer Biomet Holdings (ZBH). On Wednesday, The value of composite uptick trades was $16.07 million, whereas, the value of composite downtick trades was $24.17 million and the ratio between the two was 0.67, indicating selling on strength. Traders involved in block trades booked profits in their holdings as seen in the transactions on downticks valued at $7.75 million. The negative money flow of ($7.75 million) shows selling on strength. Zimmer Biomet Holdings (ZBH) gained $0.59 intraday at $128.6 and registrered 0.46% for the week.
Shares of Zimmer Biomet Holdings, Inc. appreciated by 1.12% during the last five trading days but lost 1.33% on a 4-week basis. Zimmer Biomet Holdings, Inc. is up 8.15% in the last 3-month period. Year-to-Date the stock performance stands at 26.15%.
Zimmer Biomet Holdings (ZBH) : Zacks Investment Research ranks Zimmer Biomet Holdings (ZBH) as 3, which is a Hold recommendation. 12 research analysts consider that the stocks fundamentals point to a bright future, hence they rate the stock as a Strong Buy. 3 other analysts are mildly bullish on the stock and favor a Buy. A total of 7 analysts believe that the stock has a limited upside, hence they advise a Hold. The average broker rating of 22 research analysts is 1.75, which indicates as a Buy.
Zimmer Biomet Holdings (NYSE:ZBH): The stock opened at $127.78 and touched an intraday high of $128.73 on Wednesday. During the day, the stock corrected to an intraday low of $125.01, however, the bulls stepped in and pushed the price higher to close in the green at $128.61 with a gain of 0.47% for the day. The total traded volume for the day was 664,696. The stock had closed at $128.01 in the previous trading session.
Zimmer Biomet Holdings, Inc., formerly Zimmer Holdings, Inc. is a musculoskeletal healthcare company. The Company designs, manufactures and markets orthopedic reconstructive products; sports medicine, biologics, extremities and trauma products; spine, bone healing, craniomaxillofacial and thoracic products; dental implants, and related surgical products. The Company manages its operations through three geographic segments: the Americas, comprising principally of the United States and includes other North, Central and South American markets; Europe, comprising principally of Europe and includes the Middle East and African markets; and Asia Pacific, comprising primarily of Japan and includes other Asian and Pacific markets. The Company markets and sells products through three channels: direct to healthcare institutions, such as hospitals or direct channel accounts; through stocking distributors and healthcare dealers, and directly to dental practices and dental laboratories.